The choice of model decides which questions a program can answer. Prisys Biotech provides non-human primate (NHP) models for a range of neurological disorders, and among them the Intra-Cerebrovascular Stroke (ICH) model stands out for how closely it reproduces the human condition and how much of the downstream pathology it preserves.
Understanding Intracerebral Hemorrhagic Stroke (ICH)
Intracerebral Hemorrhagic Stroke, commonly referred to as ICH, is a severe type of stroke characterized by bleeding within the brain tissue or ventricles. It can arise from multiple factors, including hypertension, coagulopathy, anticoagulant therapy, brain trauma, aneurysms, arteriovenous malformations, and brain tumors. Quick and effective control of bleeding is critical in managing ICH, while anti-ischemic treatments can mitigate permanent brain injury following the event.
The two problems pull in opposite directions: measures that stop the bleeding can compromise perfusion, and measures that protect ischemic tissue can worsen the hematoma. That trade-off is hard to study in a model that captures only one half of the pathology.
How The Model Is Induced
The ICH model at Prisys Biotech is induced using intracranial collagenase, which replicates the hemorrhagic stroke by breaking down the blood-brain barrier and allowing blood to enter the brain tissue, simulating the natural occurrence of ICH in humans. Collagenase digests the basal lamina of cerebral vessels, so the bleeding that follows starts from the vessel wall rather than from a needle track, and the resulting hematoma expands into surrounding tissue in a way that a simple blood injection does not reproduce.
What A Study Measures
- Neurological deficit assessment. Behavioral and cognitive testing establishes how far the stroke has affected the animal, and provides the functional baseline against which a treatment is judged. Where finer resolution is needed, an AI-based NHP Behavior Analysis System can quantify movement and posture continuously instead of at scheduled observation points.
- Imaging. Clinical Imaging modalities such as Magnetic Resonance Imaging (MRI) are used to visualize the brain and quantify the extent of hemorrhage, giving a structural read on lesion size and location that behavior alone cannot supply.
- Physiological parameters. Blood pressure (BP), heart rate (HR) and body temperature (Body Tm) are monitored throughout, because the systemic response to the bleed shapes the outcome as much as the bleed itself.
- Histopathology. Cellular and tissue-level changes in the brain are examined after the study, which shows the extent of damage and whether a candidate treatment altered it.
Why The Model Is Useful
High relevance to human conditions. The NHP model closely mimics human ICH, which gives a platform for studying the disease and testing interventions in a setting that translates.
Breadth of evaluation. Imaging, physiological monitoring and histopathology together describe the disease and the effect of treatment from several angles, so a negative result can be traced to a specific step rather than treated as a single verdict.
Customizable protocols. Protocols can be adapted to the research question, which matters because a study designed to test hemostatic control and a study designed to test neuroprotection need different timelines and endpoints.
Clinical Relevance And Application
The Intra-Cerebrovascular Stroke (ICH) model developed by Prisys Biotech is a working tool for clinical translation, and its relevance rests on the same feature that makes it useful preclinically: it reproduces the human condition closely enough that findings carry over. Programs use it to select candidates and to decide which endpoints are worth carrying into a first-in-human study.
Testing Efficacy And Safety
The ICH model supports evaluation of both efficacy and safety. By replicating the pathophysiology of human ICH, it lets researchers observe the pharmacokinetics and pharmacodynamics of new drugs in a controlled setting, which helps identify candidates that can proceed to clinical trials and shortens the path to that decision.
Safety questions deserve equal weight here. A hemostatic agent that works in a normal vessel may behave differently in a vessel whose wall has been digested by collagenase, and a neuroprotectant that looks clean in healthy animals may interact with the repair process after a bleed.
Optimizing Treatment Protocols
The model also allows comparison of treatment protocols, which is how the practical questions get answered. By testing different dosages, delivery methods and therapeutic combinations, researchers can narrow the protocol before it reaches a clinical setting, where the cost of getting the dose or the timing wrong is much higher. Rapid control of Acute hemorrhage is the first objective in any such protocol, and the model is built to show whether that objective was met.
For programs in pharmaceutical development and neurological research, the combination of imaging, physiology, behavior and histology is what makes a candidate decision defensible.
For more information on Prisys Biotech's ICH model and other neurological disease models, contact us via email at bd@prisysbiotech.com.
